PRISM-TB is an international, seamless, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, multi-arm multi-stage (MAMS), noninferiority Phase 2/3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB). In Stage 1, participants will be randomized among one of three treatment arms (one control and two experimental). Following the interim analysis (at the end of Stage 1) based on DOOR outcome comparisons and the entirety of the data, one of the four possible experimental strategies will be identified and continue into Stage 2. In Stage 2, participants will be randomized among one of two treatment arms (one control and one experimental).
The trial objective is to identify, among participants with fluoroquinolone-susceptible multidrug-resistant/rifampicin-resistant tuberculosis (FQ-S MDR/RR-TB), the preferred BPaLM strategy of 13 or 17 weeks for participants stratified to receive shorter treatment and 17 or 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, and to evaluate whether this BPaLM strategy has noninferior efficacy to the control strategy at Week 73.

开始日期2025-11-01

申办/合作机构

The University of California, San Francisco

[+1]

ChiCTR2500108732

/ Not yet recruiting临床2期IIT

A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets with Delamanid in Patients with Rifampin-resistant Tuberculosis (JD-RISE)

开始日期2025-09-10

申办/合作机构

首都医科大学附属北京胸科医院

[+1]

100 项与盐酸莫西沙星相关的临床结果

登录后查看更多信息

100 项与盐酸莫西沙星相关的转化医学

登录后查看更多信息

100 项与盐酸莫西沙星相关的专利（医药）

登录后查看更多信息

9,051

项与盐酸莫西沙星相关的文献（医药）

2025-12-31·Gut Microbes

A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity

Article

作者: de Gunzburg, Jean ; Burdet, Charles ; Corbel, Tanguy ; Ferreira, Stéphanie ; Olivares, Carlos ; Guedj, Jeremie ; Ruppé, Etienne ; Andremont, Antoine

Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.

2025-12-01·JOURNAL OF COLLOID AND INTERFACE SCIENCE

High-efficiency photocatalytic degradation of multiple quinolone antibiotics using a hybrid heterojunction with synergistic doping of boron and bismuth

Article

作者: Chen, Licheng ; Xin, Junwei ; Wang, Lei ; Jing, Ruosong ; Ren, Jie ; Zhang, Huihui ; Wang, Xudong ; Sun, Han ; Dong, Yonghao

The practical application of conventional photocatalytic technologies in aquatic environmental remediation is significantly limited by rapid charge recombination and insufficient redox capacity. Theoretical calculations and experimental characterization confirmed that the synergistic co-doping of boron (B) and bismuth (Bi) induced tailored modifications to the band structures and Fermi level potential of g-C₃N₄ (CN) and ZnIn₂S₄ (ZIS), respectively, successfully transforming the type-II CN/ZIS heterojunction into an S-scheme B-doped CN/Bi-doped ZIS (BCN/BZIS) heterojunction. The subsequent integration of Cd_0.5Zn_0.5S (CZS) into the BCN/BZIS heterojunction introduced additional type-II and S-scheme photogenerated carrier transfer pathways, thereby establishing a hybrid BCN/BZIS/CZS heterojunction. This configuration exhibited exceptional reduction capacity and optimized photogenerated carrier separation and migration efficiency, leading to excellent degradation performance for gatifloxacin ((26.89 ± 1.94) × 10^-2 min^-1), sparfloxacin ((10.48 ± 2.03) × 10^-2 min^-1), moxifloxacin ((8.43 ± 1.02) × 10^-2 min^-1), and gemifloxacin ((4.13 ± 0.13) × 10^-2 min^-1). The degradation disparities among these quinolone antibiotics were systematically elucidated through analyses of steric hindrance, frontier molecular orbital energies, Mulliken charge distribution, reaction sites, and active species contribution rates. This study offers guidance for the systematic development of heterojunction photocatalysts to address fluoroquinolone pharmaceutical pollutants in aquatic ecosystems.

2025-12-01·Current HIV/AIDS Reports

An Update on the Clinical Management of HIV and Tuberculosis Co-Infection in Pregnancy: TB Preventative Therapy, Long-Acting ARVs, and Bedaquiline-Based Regimens

Review

作者: Crocker-Buque, Tim ; Moso, Michael A ; Denholm, Justin T ; Singh, Kasha P

Abstract:

Purpose:

This update addresses HIV/TB co-infection management in pregnancy, focusing on new treatment options.

Recent Findings:

Pregnancy with HIV increases TB risk and worsens treatment outcomes. While long-acting antiretroviral therapies (LA-ART) like cabotegravir/rilpivirine and lenacapavir exist, data on their safety and efficacy in pregnant individuals are limited. Treating both HIV and TB is crucial, but pregnancy’s physiological changes complicate drug management. Standard ART and TB preventive therapy (TPT) with isoniazid are recommended after excluding active TB, despite some concerns about adverse outcomes when combined with ARV treatment. For active drug-resistant TB, the new 6-month BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) is not recommended in pregnancy due to limited safety data on pretomanid. Instead, a 9-month regimen is preferred, though bedaquiline and pretomanid are likely safe. More research on these new therapies in pregnant populations is needed.

Summary:

While standard ART remains the recommended approach for HIV/TB co-infection in pregnancy, further research is crucial to establish the safety and efficacy of newer LA-ART and bedaquiline-based TB regimens in this high-risk population. Concerns around the safety of TPT in pregnancy remain unanswered and further prospective research is urgently needed.

334

项与盐酸莫西沙星相关的新闻（医药）

2025-10-30

·医药健闻

拜耳被曝剥离王牌抗生素由红杉中国接盘；赛默飞世尔收购临床试验数据管理公司Clario | 日报

全球医疗行业每日重点资讯文 | 苏丁企业动态新桥生物（NovaBridge Biosciences）宣布，公司已完成名称变更，由“I-Mab”正式更名为“新桥生物”。此项更名决议已获得公司于2025年10月24日召开的特别股东大会高票通过，并获董事会批准。公司拟在香港进行首次公开募股（IPO），并通过在美国纳斯达克（NASDAQ）和香港联交所（HKEX）双重上市，扩大对全球资本和创新资源的连接。基于全新“中心-辐射（hub-and-spoke）”业务模式，公司已成立子公司Visara Inc. ，并已收购新型双特异性生物分子VIS-101（靶向VEGF-A/ANG2）。公司核心资产givastomig--一款潜在同类最佳地位的Claudin 18.2×4-1BB双特异性抗体，正按照此前公布的投资计划持续推进研发。赛默飞世尔(Thermo Fisher Scientific)宣布，将从由Astorg和Nordic Capital、Novo Holding以及Cinven领导的股东集团手中收购临床试验数据管理公司Clario Holdings。在收购交易完成之后，Clario将并入赛默飞世尔旗下的实验室产品与生物制药服务业务部门。此举符合赛默飞世尔扩大其在临床试验数据管理领域能力的战略。葛兰素史克(GSK)公布2025年第三季度业绩。季度营业额85.47亿英镑，上年同期为80.12亿英镑。季度营业利润25.93亿英镑，上年同期为1.89亿英镑。季度归属股东的净利润20.13亿英镑，上年同期净亏损5800万英镑。产业动态 CareerIn投行PEVC消息显示，拜耳集团已正式签署协议，将其旗下经典抗生素药物Avelox（莫西沙星）的相关业务及资产出售给红杉中国。根据双方签署的股权购买协议，本次交易规模预计在1.6亿至2.6亿欧元之间。核心标的为Avelox的知识产权、全球品牌所有权及商业权益。这笔交易是拜耳全球产品线瘦身、聚焦核心优势领域的又一举措。Avelox（莫西沙星）是由德国拜耳公司研制的超广谱喹诺酮类抗感染药物。礼来正携手沃尔玛，扩大减肥药Zepbound的销售版图。该药预计11月中旬在全国沃尔玛药店全面上市。届时，沃尔玛药店会提供所有获批剂量的Zepbound，最低剂量自费每月起价349美元。默沙东与卫材联合宣布，因3期LEAP-012研究未达到总生存期（OS）主要终点，双方将终止PD-1抑制剂Keytruda与酪氨酸激酶抑制剂Lenvima联合标准经动脉化疗栓塞术（TACE）用于不可切除、非转移性肝细胞癌（HCC）的研发计划。这一决定为该联合疗法坎坷的肝癌研发之路再添波折。华大智造宣布将通过其美国子公司与瑞士生物科技企业Swiss Rockets AG达成技术授权合作。根据协议，华大智造将一项名为“CoolMPS”的测序技术相关专利、商标、专有技术和软件以独占许可/普通许可的方式授权予Swiss Rockets，用于在除亚太及大中华区以外的全球市场进行开发、生产及商业化。此次合作正常履约至独占授权期满，华大智造合计将获得不低于1.2亿美元的授权许可费。科兴生物生产的三价流感疫苗安尔来福（0.5ml/剂）扩龄申请获得国家药品监督管理局(NMPA)批准，接种对象增加6-35月龄人群，适用人群扩大至6月龄及以上全人群。本月内，科兴四价流感疫苗（0.5ml/剂）和三价流感疫苗（0.5ml/剂）已相继获批扩龄，至此该公司生产的季节性流感疫苗已实现6月龄及以上人群接种剂型统一。上海爱科百发生物医药技术股份有限公司宣布，其预防呼吸道合胞病毒（RSV）感染的全人源单克隆抗体注射液AK0610的II期临床研究已正式启动。该临床试验是一项在中国健康婴儿中评价AK0610注射液的安全性、耐受性和药代动力学特征的多中心、随机、双盲、安慰剂对照、剂量递增II期研究，由首都医科大学附属北京儿童医院倪鑫教授与四川大学华西第二医院刘瀚旻教授共同牵头主持。这标志着爱科百发在RSV预防领域取得关键性进展。中国制药企业今年达成的向海外出售其资产的交易数量创历史新高，推动生物科技股飙升。投资者押注中国将成为全球药物研发的一股推动力量。数据显示，2025年前八个月，中国企业已达成93笔海外许可交易(国内企业出售其自主研发药品的海外权利)，总价值达850亿美元。与此同时，江苏恒瑞和康方生物等公司临床试验和早期开发药物的快速增长表明，中国生物技术公司向全球制药商出售其药品的趋势将持续下去。联系美通社 +86-10-5953 9500 info@prnasia.com

财报并购IPO

2025-10-30

·思齐俱乐部

拜耳剥离重磅抗生素业务

来源：CareerIn投行PEVC 10月29日，CareerIn投行PEVC获悉：德国制药巨头拜耳集团（Bayer AG）已同意将其旗下抗生素药物Avelox（莫西沙星）相关业务及资产出售给红杉中国（HSG）。双方已签署股权购买协议（SPA），交易规模预计在1.6亿欧元至2.6亿欧元之间。此次交易涉及的核心资产包括Avelox的知识产权（IP）、品牌所有权及全球商业权益。汇丰银行（HSBC）担任拜耳方面的独家财务顾问，而上海浦东发展银行（SPDB）为收购方红杉中国提供了贷款融资支持。公开资料显示，Avelox作为拜耳研发的广谱抗生素，主要用于治疗社区获得性肺炎、急性鼻窦炎、慢性支气管炎急性发作等上下呼吸道感染，同时对皮肤和软组织感染也具有疗效。该药物于1999年获得美国食品药品监督管理局（FDA）批准上市，其销售额在2012年达到峰值后逐步下滑。中国市场对Avelox的全球销售贡献尤为显著。华润双鹤药业2023年发布的公告显示，该药物最新可查的全球销售额为2021年的7200万美元。尽管目前中国已有海南爱科制药、正大天晴、华润双鹤等22家企业生产该药物的仿制药，但拜耳的原研品牌在2021年仍占据中国市场40%的份额，展现出强大的品牌认可度。业内分析认为，此次交易折射出中国过期专利品牌药（off-patent branded drugs）市场的投资价值正在凸显。当前跨国药企普遍战略转型聚焦创新药管线，为专注该领域的投资机构创造了机会。这一趋势在2024年底已有明确体现——CBC集团与穆巴达拉投资公司联合以6.8亿美元收购比利时药企UCB的中国业务，涵盖开浦兰（Keppra）、维派特（Vimpat）等知名品牌及珠海生产基地，交易完成后成立的NeuroGen Pharma已开始布局神经健康领域创新。拜耳集团通过出售Avelox可快速回笼1.6亿-2.6亿欧元资金，用于投入创新药研发或高潜力业务。此前拜耳在华合作终止（如华堂宁）后更凸显对高效资产的筛选倾向，剥离非核心的成熟药业务可提升整体资产周转效率。从行业周期来看，2025-2029年全球将迎来新一轮医药专利悬崖，预计到期药物年销售额规模达1800亿美元。与以往不同的是，中国资本已成为过期专利药资产交易的关键参与者，此次红杉中国收购Avelox业务正是这一趋势的缩影。思齐圈公开课报名中！点击阅读原文了解更多

并购专利到期

2025-10-30

·北京医学感染与传染研究

抗菌化疗杂志 80卷 7-10期、增刊2、4期

Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期 https://academic-oup-com.libproxy1.nus.edu.sg/jac/issue REVIEWS（综述） 1 The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review 抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述 Konstantinos Alexakis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771, 2 To be or not to be: the non-antimicrobial properties of common antimicrobials 生存还是毁灭：常见抗菌药物的非抗菌特性 Shivakumar Narayanan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783, SYSTEMATIC REVIEWS（系统综述） 3 Antibiotic-induced Bartter-like syndrome: a systematic review 抗生素诱发的巴特综合征样表现：系统综述 Megha Priyadarshi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791, 4 Liposomal amphotericin B prophylaxis in paediatrics: a systematic review 两性霉素B脂质体预防性用药在儿科中的应用：系统综述 Emma V Thorley and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802, ORIGINAL RESEARCH（论著） 5 Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study 婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究 Sarah F Hak and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812, 6 Plasmodium falciparum isolates: ex vivo drug response 恶性疟原虫分离株：体外药物反应 Edem Adika and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822, 7 Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia 低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827, 8 Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England 探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法 Ming Xuan Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836, 9 Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study 新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究 Yulia Butscheid and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848, 10 Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析 Alessandro Cozzi-Lepri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859, 11 Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model 基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型 Diego Vera-Yunca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868, 12 Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine 线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关 J R Macdonald and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877, 13 Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium 米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性 Kay Htaik and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884, 14 Early use of the novel antifungal rezafungin: a case series and literature review 新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述 H C Davidson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892, 15 Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach 基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量 Gisela Myrian de Lima Leite Dalla Rosa and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901, 16 Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade 过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关 Aliya El Nagar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906, 17 An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections 一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响 Mariagrazia Ciardo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914, 18 Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients 利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估 Xiaoping Shi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925, 19 Rapid susceptibility testing on urine for antimicrobial stewardship in general practice 全科实践中的尿液快速药敏试验助力抗菌药物管理 Patrick D J Sturm and Tanja Schülin Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932, 20 Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains 利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941, 21 In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains 新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性 Marie L G Attwood and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946, 22 Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions 中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性 Nadiia Mosiichuk and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950, 23 Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China 中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征 Zeqiang Zhan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963, 24 High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study 根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集 Zhengyu Luo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971, 25 Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus 抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响 Aliona S Rosca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979, 26 Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study 肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究 Lijuan Feng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987, 27 Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875 多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征 Jonathan Koong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992, 28 Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum 改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较 Doris Hillemann and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996, 29 Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations 由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转 Paschalis Paranos and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006, 30 Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France 瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构 Sofie M Edslev and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015, 31 Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections 抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估 Nischal Ranganath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024, 32 Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control 肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法 Ana Beatriz Gonçalves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031, 33 Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori 抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性 Paweł Krzyżek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043, 34 A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro 生殖支原体体外诱导产生的新型阿奇霉素耐药突变 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050, RESEARCH LETTERS（研究信函） 35 Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations 婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度 Jeffrey Harrington and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053, 36 Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis 两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法 Natacha Mrozek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056, 37 Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis? 头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？ Alexandra Morin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058, LETTER TO THE EDITOR（致编辑的信） 38 Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint 单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点 Miguel Villamarín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060, Journal of Antimicrobial Chemotherapy Volume 80, Issue 8 抗菌化疗杂志 80卷 8期 https://academic-oup-com.libproxy1.nus.edu.sg/jac/issue Review(综述) 1 World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’ 世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇” Vazhayil Hari Krishnaprasad and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069 Original Research(论著) 2 Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023) 氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结 Helio S Sader and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079 3 High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid 利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究 Hitoshi Kawasuji and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091 4 Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium 缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析 Yukitaka Hayashi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099 5 Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial 为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验 Nusrat Shafiq and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108 6 An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy 用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型 Cole McGrath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116 7 Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa 黏液型铜绿假单胞菌纸片扩散法的优化与改进 Aixin Wang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125 8 HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022 乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查 Christine Watera and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134 9 Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women 与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究 Sharana Mahomed and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144 10 Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study 接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究 Javier García-Abellán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157 11 Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model 慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究 Midas B Mulder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168 12 Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据 Roberta Gagliardini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178 13 Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial 病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验 Hsin-Yun Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186 14 Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia 青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究 Pernilla Kihlberg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193 15 Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202 16 Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway 齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌 Yun-Dan Zheng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213 17 Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study 阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究 Tom C Zwart and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225 18 48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析 Elisa de Lazzari and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233 19 The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time 多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响 Trenton Honda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240 20 Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales 一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估 Christian Moguet and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246 21 Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究 Matteo Rinaldi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256 22 Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus 靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染 Robin H G A van den Biggelaar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268 23 Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm 基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279 24 Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy 意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件 Andrea Brenciani and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284 25 Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022 2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征 Corentin Poignon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294 26 Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections 具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁 Ye Jin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304 27 Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB 贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性 Simon E Koele and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313 28 Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study 头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究 Dimitrios Basoulis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322 Research Letters(研究信件) 29 Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring 达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告 Carlo Pallotto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324 30 A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs 韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174） Hyeonwoo Cho and Kun Taek Park Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326 31 Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report 时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告 Layla Pagnucco and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330 32 Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48 土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征 Astrid Rasmussen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331 Letters to the Editor(致编辑的信) 33 Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital 述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究 Jianjun Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332 34 Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response 产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复 Gulhadiye Avcu Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333 Corrections(更正) 35 Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD) 更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334 36 Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs 更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335 37 Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics 更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336 Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2 抗菌化疗杂志 80卷增刊2期 https://academic-oup-com.libproxy1.nus.edu.sg/jac/issue SUPPLEMENT (补充) CANWARD 2007-23 加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告 Foreword(前言) 1 The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection 加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集 James C Hurley and Jean-Yves Madec Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1 Supplement Papers(补充论文) 2 Seventeen years of the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究17年（2007-2023年） George G Zhanel and Heather J Adam Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4 3 Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14 4 Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26 5 Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023） Anissa Brahami and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34 6 Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23） Heather J Adam and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44 7 Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23 加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023 Philippe Lagacé-Wiens and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53 8 Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23） Laura F Mataseje and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61 9 Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23) 加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23） Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71 10 Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23) 加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果 Andrew Walkty and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82 Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期 https://academic-oup-com.libproxy1.nus.edu.sg/jac/issue VIEWPOINT（观点） 1 Classifying patients with invasive fungal disease: towards a unified case definition? 侵袭性真菌病患者分类：能否达成统一的病例定义？ Mehmet Ergün and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343, SYSTEMATIC REVIEW（系统综述） 2 Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis 早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析 ZhaoYi Tan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360, ORIGINAL RESEARCH（论著） 3 Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium 屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定 Maria Laura Ferrando and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368, 4 Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响 Rebecka Papaioannu Borjesson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374, 5 Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks 随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响 Parul Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383, 6 Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea 基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据 So Yun Lim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390, 7 A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme 摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准 Aymeric Jacquemin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398, 8 Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya 2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征 Diana Imoli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407, 9 Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection 经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响 Tao-Hung Ou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416, 10 Safety of topical tobramycin powder during operative treatment of fractures 骨折手术中使用局部妥布霉素粉末的安全性 Gregory M Schrank and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420, 11 Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS 复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析 Rinko Lau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427, 12 Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England 从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌 Satheesh Nair and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432, 13 Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics 克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用 Siddharth Singh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441, 14 Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446, 15 Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用 Xuemin Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458, 16 A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology 采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究 Joseph Meletiadis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465, 17 Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study 万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析 M Del Monte and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473, 18 Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient 异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现 Martyna Pociupany and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483, 19 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486, 20 Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database 使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析 Yongseop Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495, 21 Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024 2024年中国河南省HIV-1感染者传播耐药情况 Jinjin Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502, 22 Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性 Makiko Noda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512, 23 In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization 头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征 Clara Moretó-Castellsaguéand others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523, 24 Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates 达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用 David Luque Paz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529, 25 Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation 伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响 Wenjie Cui and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540, 26 Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up 加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响 Freshwork Ayalew Abegaz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549, RESEARCH LETTERS（研究快信） 27 TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient 治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染 Giovanni Mulé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552, 28 Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage 城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759 Xinyuan Qiu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555, 29 Characterization of multiresistance gene optrA in Bacillus subtillis from China 中国枯草芽孢杆菌中多重耐药基因optrA的特征分析 Yongliang Che and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557, 30 Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China 从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征 Fuqiang Ye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560, LETTERS TO THE EDITOR（致编辑的信） 31 Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events 关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论 Mi Zhou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562, 32 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study 关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论 Satoru Mitsuboshi Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563, 33 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response 住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564, Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期 https://academic-oup-com.libproxy1.nus.edu.sg/jac/issue REVIEWS（综述） 1 Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead 长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战 Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586, 2 Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估 James C Hurley Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596, SYSTEMATIC REVIEWS（系统综述） 3 Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology 研究肺结核治疗的肺内药代动力学：方法学的系统综述 Isabella van der Feltz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608, 4 Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis 全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析 Christopher Larkin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621, ORIGINAL RESEARCH（研究论著） 5 Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium? 氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？ Paula Bierge and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629, 6 Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023 2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测 Nguyen Van Thanh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634, 7 Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia 哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性 Savan Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643, 8 Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia 连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度 Claire Roger and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653, 9 Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial 头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验 Tamara Klementová and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658, 10 Trends in antifungal use among hospitalized patients in the USA, 2018–23 2018-2023年美国住院患者抗真菌药物使用趋势 Dallas J Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664, 11 Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究 Louis Oudiane and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675, 12 In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium 甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性 Sofie Skovmand and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681, 13 A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model 基于群体药代动力学模型的左氧氟沙星剂量方案先验优化 Emmanuel Enard and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692, 14 Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis 危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析 Tingting Wu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704, 15 Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria 开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标 Irene Zaghi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713, 16 In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model 头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718, 17 Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial 健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验 Jinhee Jo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726, 18 Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application 抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示 Nathan Engel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731, 19 A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study 意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741, 20 Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study 使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究 Hiroki Katsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751, 21 Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial BALANCE临床试验中血流感染患者的临床病程 Sean W X Ong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758, 22 Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study 神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究 Qian Zeng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772, 23 Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates 肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景 Jayanth Balakuntla and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781, 24 Population pharmacokinetics of bictegravir in real-world people with HIV 现实中HIV感染者比克替拉韦的群体药代动力学 Pierre Ekobena and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789, 25 Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index 活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响 Teres Samuelsson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798, 26 Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa 在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806, 27 Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model 在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移 Solene Labaye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813, 28 Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms 针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用 Justin Halim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824, 29 Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France 2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验 L Sagaon-Teyssier and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833, 30 Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin 对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征 Emilia Cercenado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843, 31 Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA 美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构 Chih-Hao Hsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853, 32 Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii 鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征 Jingchen Hao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861, 33 Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones 各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征 Jing Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872, RESEARCH LETTERS（研究快报） 34 Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option? 奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？ Giulia Turicchi and Marco Bongiovanni Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874, 35 The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876, 36 Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas 携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播 Roberto Sierra and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879, 37 Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae 替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性 Julie Brousseau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881, LETTERS TO THE EDITOR（致编辑的信） 38 Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus 述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性 Karl Oldberg and Magnus Rasmussen Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883, 39 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究 Giancarlo Ceccarelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885, 40 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response 住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886, Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷增刊4期 https://academic-oup-com.libproxy1.nus.edu.sg/jac/issue/80/Supplement_4 SUPPLEMENT（补充） Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 FOREWORD（前言） 1 Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 James C Hurley and Alan P Johnson Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1, SUPPLEMENT PAPERS（补充论文） 2 Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions 英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向 Alasdair P MacGowan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6, 3 The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations 英国抗菌化疗学会耐药性监测项目：方法与局限性 Michael Allen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21, 4 Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35, 5 Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48, 6 Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019 英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59, 7 Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019 英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71, 8 Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019) 英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年） Carolyne Horner and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86, 9 Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future 英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来 Benjamin J Parcell and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95,

微生物疗法临床1期

100 项与盐酸莫西沙星相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00874	盐酸莫西沙星	J01MA14 S01AE07	DB00218

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
鼠疫	美国	Bayer HealthCare Pharmaceuticals, Inc.	2016-09-27
复杂腹腔感染	美国	Fresenius Kabi USA LLC	2015-04-03
呼吸道感染	中国	Bayer Vital GmbH	2009-08-11
睑缘炎	日本	Novartis Pharma AG	2006-07-26
结膜炎	日本	Novartis Pharma AG	2006-07-26
角膜溃疡	日本	Novartis Pharma AG	2006-07-26
泪囊炎	日本	Novartis Pharma AG	2006-07-26
睑腺炎	日本	Novartis Pharma AG	2006-07-26
角膜炎	日本	Novartis Pharma AG	2006-07-26
脓肿	美国	Bayer HealthCare Pharmaceuticals, Inc.	2005-11-22
腹腔感染	美国	Bayer HealthCare Pharmaceuticals, Inc.	2005-11-22
简单的皮肤和皮肤结构感染(uSSSI)	美国	Bayer HealthCare Pharmaceuticals, Inc.	2005-11-22
急性支气管炎	日本	Bayer Yakuhin Ltd.	2005-10-11
细菌感染	日本	Bayer Yakuhin Ltd.	2005-10-11
咽喉炎	日本	Bayer Yakuhin Ltd.	2005-10-11
肺炎	日本	Bayer Yakuhin Ltd.	2005-10-11
慢性呼吸道感染	日本	Bayer Yakuhin Ltd.	2005-10-11
继发感染	日本	Bayer Yakuhin Ltd.	2005-10-11
鼻窦炎	日本	Bayer Yakuhin Ltd.	2005-10-11
扁桃体炎	日本	Bayer Yakuhin Ltd.	2005-10-11

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
耐多药结核病	临床3期	巴西	Global Alliance for TB Drug Development	2018-07-30
耐多药结核病	临床3期	格鲁吉亚	Global Alliance for TB Drug Development	2018-07-30
耐多药结核病	临床3期	马来西亚	Global Alliance for TB Drug Development	2018-07-30
耐多药结核病	临床3期	菲律宾	Global Alliance for TB Drug Development	2018-07-30
耐多药结核病	临床3期	俄罗斯	Global Alliance for TB Drug Development	2018-07-30
耐多药结核病	临床3期	南非	Global Alliance for TB Drug Development	2018-07-30
耐多药结核病	临床3期	坦桑尼亚	Global Alliance for TB Drug Development	2018-07-30
耐多药结核病	临床3期	乌干达	Global Alliance for TB Drug Development	2018-07-30
多重耐药性肺结核	临床3期	格鲁吉亚	Global Alliance for TB Drug Development	2015-02-01
多重耐药性肺结核	临床3期	肯尼亚	Global Alliance for TB Drug Development	2015-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06363292 (CTgov)	临床1期	细菌性结膜炎	37	PRO-231 (PRO-231)	餘憲蓋蓋顧夢繭艱衊淵 = 艱鑰鬱壓廠鹹艱襯網構鹽壓築鑰遞遞範築壓選 (糧鏇積齋襯窪繭蓋醖襯, 簾蓋願艱積鏇願齋築襯 ~ 壓窪積衊築繭廠築構範) 更多	-	2025-06-15
				VIGAMOXI® (VIGAMOXI®)	餘憲蓋蓋顧夢繭艱衊淵 = 膚顧壓願襯齋繭獵蓋衊鹽壓築鑰遞遞範築壓選 (糧鏇積齋襯窪繭蓋醖襯, 鏇艱顧壓觸鬱簾蓋網蓋 ~ 餘鏇鏇積窪鹹襯窪夢鏇) 更多
NCT06785090 (CTgov)	临床4期	白内障 \| 黄斑水肿	87	Dexamethasone phosphate 0.1%+Moxifloxacin 0.5% ophthalmic solution+Bromfenac (Bromfenac Group)	願鬱積簾築網構網願襯(鬱衊簾夢繭壓窪選觸範) = 壓夢鏇積窪遞鏇鹹壓積憲構網膚廠積繭餘觸鹽 (憲憲衊夢膚淵鑰淵淵鏇, 15.4) 更多	-	2025-05-06
				Dexamethasone phosphate 0.1%+Moxifloxacin 0.5% ophthalmic solution (Control Group)	願鬱積簾築網構網願襯(鬱衊簾夢繭壓窪選觸範) = 淵遞願憲顧範夢齋繭獵憲構網膚廠積繭餘觸鹽 (憲憲衊夢膚淵鑰淵淵鏇, 14.8) 更多
NCT04750655 (ARIES, CTgov)	临床4期	肠道疾病	108	Moxifloxacin (Intraoperative Antibiotics (Abx) Only; no Postoperative Topical Antibiotics)	齋範鹽淵齋築膚壓鏇窪(窪廠選衊鏇簾觸壓憲糧) = 觸鏇範鬱遞繭顧願鹹糧窪構繭餘繭壓觸鬱鬱簾 (醖網齋網遞範夢構淵憲, 0) 更多	-	2025-03-28
				Moxifloxacin (Intraoperative Antibiotics (Abx); Postoperative Topical Antibiotics Four Times a Day for 1 Week)	齋範鹽淵齋築膚壓鏇窪(窪廠選衊鏇簾觸壓憲糧) = 憲齋鬱醖膚繭襯構選齋窪構繭餘繭壓觸鬱鬱簾 (醖網齋網遞範夢構淵憲, 0) 更多
NCT05671029 (CTgov)	临床1期	-	64	moxifloxacin placebo (Group 1)	窪鹽網築壓憲夢衊構簾(齋糧艱糧餘膚壓窪積獵) = 壓獵齋餘齋鏇鹽淵糧簾淵醖鬱鬱夢壓遞顧範鬱 (鏇蓋糧範夢夢餘窪淵窪, 15.198) 更多	-	2025-03-14
				Pritelivir placebo, moxifloxacin and moxifloxacin placebo (Group 2a)	窪鹽網築壓憲夢衊構簾(齋糧艱糧餘膚壓窪積獵) = 糧網鹹憲遞鬱範顧繭簾淵醖鬱鬱夢壓遞顧範鬱 (鏇蓋糧範夢夢餘窪淵窪, 17.208) 更多
NCT04179500 (PaSEM, CTgov)	临床2期	多重耐药性肺结核 \| 耐多药结核病	26	BPaMZ (BPaMZ)	觸簾築鑰觸襯憲餘觸鏇(夢選網遞構鑰鹽襯夢鏇) = 簾觸餘願築鏇壓襯膚觸製衊鏇餘窪醖鏇積艱鏇 (夢憲糧築淵廠鬱積鬱蓋, 97.3) 更多	-	2024-09-19
				moxifloxacin+bedaquiline+pyrazinamide (BPaMZ Baseline)	蓋築窪壓艱簾膚鬱醖選(鹹壓構鹽製齋顧繭簾蓋) = 築艱艱壓範憲醖築淵獵願壓獵願鹽鑰膚積淵製 (淵蓋襯鏇鏇鏇鹽鑰鑰觸, 醖糧餘衊艱構鹹鏇廠憲 ~ 選憲構築襯製窪觸壓窪) 更多
NCT03338621 (SimpliciTB, Pubmed \| Lancet Infect Dis)	临床2期	肺结核	455	Bedaquiline-pretomanid-moxifloxacin-pyrazinamide (BPaMZ) 4 months	顧憲鹽壓遞夢膚鹹繭繭(醖齋鑰選鑰艱鑰鏇顧顧) = three participants [1%] 衊製觸夢鏇襯鏇選願衊 (憲齋鏇窪淵範繭鏇獵範 ) 更多	积极	2024-09-01
NCT02589782 (TB-PRACTECAL, Pubmed) 人工标引	临床2/3期	广泛耐药结核病	552	rifampicin (Standard care)	構鏇繭簾醖製網繭鏇範(淵糧願獵網鹹觸積遞願) = 鹽製齋憲鏇獵鏇簾餘餘顧糧膚鏇鑰選蓋鹽淵壓 (繭蓋製範壓壓獵積窪蓋 ) 更多	积极	2024-02-01
				rifampbedaquilinepretomanidlinezolidmoxifloxacin (BPaLM)	構鏇繭簾醖製網繭鏇範(淵糧願獵網鹹觸積遞願) = 鬱廠構艱鬱艱鬱獵醖獵顧糧膚鏇鑰選蓋鹽淵壓 (繭蓋製範壓壓獵積窪蓋 ) 更多
NCT03338621 (SimpliciTB, CTgov)	临床2/3期	多重耐药性肺结核 \| 耐多药结核病	455	ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR)	廠構膚齋遞鹹憲壓蓋衊 = 簾齋壓範遞願憲繭壓鏇衊鏇觸衊鬱簾醖膚憲襯 (廠築製簾獵鏇淵壓憲蓋, 餘蓋齋餘艱鹽齋艱簾鹽 ~ 齋鬱鹽膚糧膚淵膚廠顧) 更多	-	2023-11-08
				4BPaMZ (Drug Sensitive-TB 4BPaMZ)	廠構膚齋遞鹹憲壓蓋衊 = 選餘齋鬱蓋顧醖糧鹹憲衊鏇觸衊鬱簾醖膚憲襯 (廠築製簾獵鏇淵壓憲蓋, 鑰構鹽壓憲遞遞鏇鑰齋 ~ 襯網簾淵糧夢鹽廠襯壓) 更多
NCT02800785 (CODA, CTgov)	N/A	阑尾炎	1,552	Moxifloxacin+Cefoxitin+Ertapenem (Antibiotics Therapy Arm)	壓觸齋窪範憲築廠鹽窪(憲餘餘廠廠繭構簾餘獵) = 憲餘窪憲網範築構壓選衊簾積繭廠壓艱壓願願 (築窪淵簾壓餘選襯齋選, 0.13) 更多	-	2023-04-18
				Appendectomy (Appendectomy Arm)	壓觸齋窪範憲築廠鹽窪(憲餘餘廠廠繭構簾餘獵) = 襯襯顧襯鹹蓋築鑰範鹹衊簾積繭廠壓艱壓願願 (築窪淵簾壓餘選襯齋選, 0.13) 更多
NCT02589782 (TB-PRACTECAL, Pubmed \| N Engl J Med)	临床2/3期	利福平耐药结核病	301	Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)	夢繭餘願齋獵觸繭淵齋(鏇廠獵壓壓積鬱鹽夢遞) = 構觸顧網壓鏇夢鏇艱繭築壓齋鬱糧獵糧範夢憲 (衊淵構繭願築淵積醖網 )	积极	2022-12-22